Summary: SGLT-2 inhibitors are an important group of drugs with pleiotropic effects. SGLT-2 inhibitors have well-established clinical indications in the treatment of: type 2 diabetes, chronic kidney disease, heart failure with reduced left ventricular ejection fraction and heart failure with preserved left ventricular ejection fraction. These drugs have an antihypertensive effect by reducing body weight, increasing natriuresis and osmotic diuresis, reducing vascular stiffness, reducing SNS activity, improving vascular endothelial function, beneficial effect on intestinal microbiota, and reducing uric acid levels. The results of clinical trials indicate that the use of SGLT-2 inhibitors reduces systolic and diastolic blood pressure by an average of 4 mmHg and 2 mm Hg, respectively. In the ESH guidelines of 2023, SGLT-2 inhibitors were included among additional antihypertensive drugs.